Company intelligence / Profile preview

VeriSIM Life

San Francisco, California, United Statesverisimlife.com ↗

Ownership: Private
Development stage: Preclinical

Overview

VeriSIM Life has demonstrated rapid advancement of its lead asset PT001 for pulmonary arterial hypertension to pre‑IND status in under three years—a process that typically takes six years—shocasing significant acceleration of drug development timelines using its AI-powered BIOiSIM® platform. The company’s approach has enabled partners like Mayo Clinic and Debiopharm to move candidates toward clinical trials faster than traditional methods allow. No published human clinical results yet.

Therapeutic areas: OncologyMetabolic DisordersRare DiseasesPsychiatryCardiovascular
Modalities: Small moleculeBiologicPeptidesAntibody
Industry: Drug Discovery Services

Partnerships

Mayo ClinicDebiopharmDaiichi-SankyoClarivate AnalyticsTotal Brain

Beyond the preview

Go deeper on VeriSIM Life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VeriSIM Life.

Explore the full profile